



## Preliminary Program

**Tuesday, June 7, 2005**

Welcome Reception

**Wednesday, June 8, 2005**

### Morning Sessions

- 08:30 Welcome  
Douglas Richman, University of California/VA Medical Center, San Diego, USA
- 08:40 Plenary

### CLINICAL IMPLICATIONS OF RESISTANCE

Chairs: Douglas Richman, University of California/VA Medical Center, San Diego, USA  
Andrew Zolopa, Stanford University, USA

- 09:25 **Mother to Child Transmission**
- 10:05 Mother to Child Transmission Roundtable Discussion
- 10:35 BREAK

Chairs: Douglas Richman, University of California/VA Medical Center, San Diego, USA  
Andrea De Luca, Università Cattolica del Sacro Cuore, Italy

- 11:05 **Prediction of Clinical Response**
- 12:00 Prediction of Clinical Response Roundtable Discussion
- 12:30 LUNCH

### Afternoon Sessions

- Chair: Douglas Richman, University of California/VA Medical Center, San Diego, USA
- Discussants: Andrew Zolopa, Stanford University, USA  
Andrea De Luca, Università Cattolica del Sacro Cuore, Italy
- 14:00 Poster Viewing  
Clinical Implications of Resistance  
New Resistance Technologies and Interpretations
- 16:00 Roundtable Facilitated Discussion: Clinical Implications of Resistance
- 17:00 Roundtable Facilitated Discussion: New Resistance Technologies and Interpretations

**Thursday, June 9, 2005**

**Morning Session**

Chairs: John Mellors, University of Pittsburgh, USA  
Randall Lanier, GlaxoSmithKline, USA

08:30 **RESISTANCE TO NEW ANTIRETROVIRAL AGENTS**

10:15 BREAK

Chairs: Brendan Larder, RDI, United Kingdom  
Michael Miller, Gilead Sciences, USA

10:45 **MECHANISMS OF HIV DRUG RESISTANCE**

12:45 LUNCH

**Afternoon Sessions**

Chair: Brendan Larder, RDI, United Kingdom

Discussants: Randall Lanier, GlaxoSmithKline, USA  
Michael Miller, Gilead Sciences, USA

14:00 Poster Viewing  
Resistance to New Antiretroviral Agents  
Mechanisms of HIV Drug Resistance

16:00 Roundtable Facilitated Discussion: Resistance to New Antiretroviral Agents

17:00 Roundtable Facilitated Discussion: Mechanisms of HIV Drug Resistance

**Friday, June 10, 2005**

**Morning Sessions**

Chairs: John Mellors, University of Pittsburgh, USA  
Deenan Pillay, University College London/Health Protection Agency, United Kingdom

08:30 **EPIDEMIOLOGY**

10:00 BREAK

Chairs: Charles Boucher, University Medical Center Utrecht, the Netherlands  
John Coffin, National Cancer Institute-Frederick, USA

10:30 **HIV PATHOGENESIS, FITNESS AND RESISTANCE**

12:15 LUNCH

**Afternoon Sessions**

Chair: John Mellors, University of Pittsburgh, USA

13:30 Plenary

Discussants: Deenan Pillay, University College London/Health Protection Agency, United Kingdom  
John Coffin, National Cancer Institute-Frederick, USA

14:15 Poster Viewing  
Epidemiology  
HIV Pathogenesis, Fitness and Resistance

16:15 Roundtable Facilitated Discussion: Epidemiology

17:15 Roundtable Facilitated Discussion: HIV Pathogenesis, Fitness and Resistance

18:15 Closing Remarks  
Brendan Larder, RDI, United Kingdom